profit from every $100 of sales.
$0$100
OPKO Health
$1.67-2.34% today
+26.5% in 1 year
1-year low $1.101-year high $1.77
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What OPKO Health sold, what it kept, and what it did with the cash.
Sales went from $1.00 billion in 2022 to $607 million in 2025, with -$226 million of profit last year.
SalesProfit
OPKO Health vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| OPKO Health | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads OPKO Health's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,004 | 863 | 713 | 607 | |
| 288 | 318 | 219 | 206 | |
| – | – | – | – | |
| -271 | -66 | 135 | -41 | |
| -328 | -189 | -53 | -226 | |
| -0.46 | -0.25 | -0.08 | -0.30 | |
| 28.7% | 36.8% | 30.6% | 33.9% | |
| – | – | – | – | |
| -32.7% | -21.9% | -7.5% | -37.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,167 | 2,012 | 2,200 | 1,932 |
| Cash | 153 | 96 | 432 | 369 |
| Total debt | 306 | 327 | 504 | 397 |
| Total liabilities | 606 | 622 | 835 | 664 |
| 1,562 | 1,389 | 1,365 | 1,268 | |
| 719 | 752 | 694 | 751 | |
| -16.1% | -7.9% | 1.6% | -6.3% | |
| -21.0% | -13.6% | -3.9% | -17.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -95 | -28 | -183 | -179 | |
| 25 | 16 | 25 | 12 | |
| -120 | -44 | -208 | -191 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 90 | 47 | |
| 19 | 11 | 11 | 11 |
Valuation
- –
- –
- –
- 0.8×
- 2.0×
- –
- –
- -15.4%
- -18.2%
- 0.0%
Profitability
- 33.9%
- -34.9%
- -37.2%
- -19.4%
- -10.9%
- -9.3%
- -16.8%
- -11.5%
- -11.9%
- 21.1%
Growth
- −15.5%
- –
- +8.5%
- –
- +3.8%
Financial health
- –
- 0.33
- 21.4%
- -2.0×
- 3.61
- 3.17
- 0.31
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 25%of 952
Bottom 9%of 883
Bottom 6%of 870
Bottom 6%of 985
What analysts expect
- Average price target
- $2.87
- Range
- $1.60 – $4.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 28, 2026 | -0.07 | -0.07 | +0.0% |
| Feb 26, 2026 | -0.04 | -0.07 | +42.9% |
| Oct 29, 2025 | 0.03 | -0.02 | +250.0% |
| Jul 31, 2025 | -0.19 | -0.12 | −58.3% |
| Apr 30, 2025 | -0.10 | -0.06 | −66.7% |
| Feb 27, 2025 | 0.01 | -0.08 | +112.5% |
| Nov 7, 2024 | 0.03 | -0.10 | +130.0% |
| Aug 7, 2024 | -0.01 | -0.09 | +88.9% |
News
Here's Why You Should Retain OPK Stock in Your Portfolio for NowYahoo Finance · Aug 24, 2026The newest story we have is from Aug 24, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
67Pass
Philip Fisher
31No pass
Peter Lynch
25No pass
Joel Greenblatt
0No pass
Charlie Munger
29No pass
Terry Smith
29No pass
Questions about OPKO Health
Is OPKO Health a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the OPKO Health AI analysis
What does OPKO Health do?
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. It is in Biotechnology.
Does OPKO Health pay a dividend?
No. OPKO Health does not pay a dividend at the moment; in 2025 it returned $47.0 million to shareholders by buying back its own shares.
Is OPKO Health stock halal?
Questionable. OPKO Health sits in a grey zone: its debt is 32% of its market value, between 30% and 33%. How we check
How has OPKO Health stock done over the past year?
Up 26.5% over the past twelve months, to $1.67. It traded between $1.10 and $1.77 and is 5.6% below its high.
Who are OPKO Health's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with OPKO Health's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.